SECsense Logo

XORTX Therapeutics Inc. Form 6-K Filing: Key Updates for January 2025

$XRTX
Form 6-K
Filed on: 2025-01-06
Source
XORTX Therapeutics Inc. Form 6-K Filing: Key Updates for January 2025

Here are the key insights extracted from the provided section of the financial report:

  1. Form Type: The document is a Form 6-K, which is used by foreign private issuers to report certain information to the SEC.
  2. Company Information:
  • Name: XORTX Therapeutics Inc.
  • Address: 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1, Canada.
  • Commission File Number: 001-40858.
  1. Filing Date: The report is dated January 6, 2025, and pertains to the month of January 2025.
  2. Annual Report Filing: The registrant has indicated that it files annual reports under Form 20-F.
  3. Signature: The report is signed by Allen Davidoff, who holds the position of Chief Executive Officer, confirming the authenticity of the filing.
  4. Exhibit: The report includes a reference to a press release dated January 6, 2025, which is attached as Exhibit 99.1.
  5. Compliance: The filing complies with the requirements of the Securities Exchange Act of 1934.

These points summarize the essential information regarding XORTX Therapeutics Inc. as reported in this Form 6-K submission. The reference to an attached press release may contain further details about the company’s activities or announcements for that period.